Orion Oyj Past Earnings Performance
Past criteria checks 6/6
Orion Oyj has been growing earnings at an average annual rate of 5.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 5.2% per year. Orion Oyj's return on equity is 35.9%, and it has net margins of 23.2%.
Key information
5.4%
Earnings growth rate
5.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 5.2% |
| Return on equity | 35.9% |
| Net Margin | 23.2% |
| Next Earnings Update | 25 Feb 2025 |
Recent past performance updates
Impressive Earnings May Not Tell The Whole Story For Orion Oyj (HEL:ORNBV)
Nov 06
We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings
May 05Recent updates
Impressive Earnings May Not Tell The Whole Story For Orion Oyj (HEL:ORNBV)
Nov 06Orion Oyj's (HEL:ORNBV) Shareholders Might Be Looking For Exit
Sep 25Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet
Sep 02Orion Oyj Just Beat EPS By 13%: Here's What Analysts Think Will Happen Next
Aug 12Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 42%?
Jul 14Orion Oyj's (HEL:ORNBV) Shares May Have Run Too Fast Too Soon
Jun 17Here's Why Orion Oyj (HEL:ORNBV) Can Manage Its Debt Responsibly
May 27We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings
May 05Orion Oyj Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Apr 27Earnings Beat: Orion Oyj Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 16Why Investors Shouldn't Be Surprised By Orion Oyj's (HEL:ORNBV) P/E
Feb 01Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet
Jan 11Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 43%?
Nov 28We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings
Nov 03Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt
Oct 05Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 51% Above Its Share Price
Aug 18Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?
Jun 21A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)
May 16Here's Why We Think Orion Oyj (HEL:ORNBV) Is Well Worth Watching
Apr 07Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt
Mar 20Orion Oyj's (HEL:ORNBV) Upcoming Dividend Will Be Larger Than Last Year's
Feb 12A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)
Feb 07Is Orion Oyj (HEL:ORNBV) Trading At A 29% Discount?
Oct 13Orion Oyj (HEL:ORNBV) Seems To Use Debt Quite Sensibly
Sep 22This Just In: Analysts Are Boosting Their Orion Oyj (HEL:ORNBV) Outlook for This Year
Jul 21Revenue & Expenses Breakdown
How Orion Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,429 | 332 | 327 | 154 |
| 30 Jun 24 | 1,259 | 232 | 305 | 144 |
| 31 Mar 24 | 1,220 | 217 | 306 | 132 |
| 31 Dec 23 | 1,190 | 217 | 299 | 127 |
| 30 Sep 23 | 1,163 | 173 | 295 | 128 |
| 30 Jun 23 | 1,354 | 306 | 308 | 137 |
| 31 Mar 23 | 1,348 | 336 | 293 | 133 |
| 31 Dec 22 | 1,341 | 350 | 284 | 133 |
| 30 Sep 22 | 1,323 | 351 | 278 | 136 |
| 30 Jun 22 | 1,072 | 202 | 252 | 123 |
| 31 Mar 22 | 1,043 | 192 | 246 | 124 |
| 31 Dec 21 | 1,041 | 194 | 238 | 118 |
| 30 Sep 21 | 1,020 | 187 | 231 | 115 |
| 30 Jun 21 | 1,029 | 192 | 235 | 118 |
| 31 Mar 21 | 1,067 | 212 | 235 | 122 |
| 31 Dec 20 | 1,078 | 220 | 245 | 123 |
| 30 Sep 20 | 1,097 | 240 | 254 | 118 |
| 30 Jun 20 | 1,131 | 260 | 258 | 121 |
| 31 Mar 20 | 1,090 | 225 | 265 | 120 |
| 31 Dec 19 | 1,051 | 200 | 264 | 119 |
| 30 Sep 19 | 1,039 | 209 | 255 | 114 |
| 30 Jun 19 | 977 | 172 | 250 | 110 |
| 31 Mar 19 | 971 | 187 | 244 | 105 |
| 31 Dec 18 | 978 | 197 | 238 | 104 |
| 30 Sep 18 | 981 | 198 | 237 | 103 |
| 30 Jun 18 | 1,001 | 206 | 236 | 102 |
| 31 Mar 18 | 1,015 | 206 | 238 | 101 |
| 31 Dec 17 | 1,034 | 219 | 237 | 99 |
| 30 Sep 17 | 1,048 | 212 | 244 | 111 |
| 30 Jun 17 | 1,065 | 242 | 246 | 114 |
| 31 Mar 17 | 1,077 | 253 | 245 | 118 |
| 31 Dec 16 | 1,074 | 249 | 243 | 118 |
| 30 Sep 16 | 1,055 | 241 | 235 | 112 |
| 30 Jun 16 | 1,036 | 214 | 233 | 108 |
| 31 Mar 16 | 1,018 | 206 | 232 | 108 |
| 31 Dec 15 | 1,016 | 208 | 235 | 108 |
| 30 Sep 15 | 1,009 | 210 | 237 | 105 |
| 30 Jun 15 | 1,009 | 214 | 237 | 103 |
| 31 Mar 15 | 1,030 | 224 | 237 | 105 |
| 31 Dec 14 | 1,015 | 211 | 235 | 106 |
| 30 Sep 14 | 1,033 | 226 | 240 | 108 |
| 30 Jun 14 | 1,031 | 226 | 242 | 108 |
| 31 Mar 14 | 1,003 | 203 | 245 | 104 |
| 31 Dec 13 | 1,007 | 206 | 248 | 102 |
Quality Earnings: ORNBV has high quality earnings.
Growing Profit Margin: ORNBV's current net profit margins (23.2%) are higher than last year (14.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORNBV's earnings have grown by 5.4% per year over the past 5 years.
Accelerating Growth: ORNBV's earnings growth over the past year (91.5%) exceeds its 5-year average (5.4% per year).
Earnings vs Industry: ORNBV earnings growth over the past year (91.5%) exceeded the Pharmaceuticals industry 10.2%.
Return on Equity
High ROE: ORNBV's Return on Equity (35.9%) is considered high.